本发明涉及作为组蛋白脱乙酰基酶（HDAC）抑制剂的异羟肟酸衍 生物。
The present invention relates to hydroxamic acid derivatives that are inhibitors of histone deacetylase (HDAC).
组蛋白脱乙酰基酶抑制剂已被证实具有抗肿瘤作用，多种有关组蛋白脱乙酰基酶抑制剂的药物临床试验正在进行中，以期成为治疗宫颈癌的一个新方向。
HDI has been proved to have antitumor activities and a number of clinical trials relating to HDI are in progress. It is expected that HDI becomes a new therapy of cervical cancer.
组蛋白脱乙酰基酶与组蛋白脱乙酰基酶抑制剂通过对组蛋白乙酰化水平的调控，影响特定基因的表达，改变细胞周期的进程。
HDAC and histone deacetylase inhibitors (HDI) can affect expression of some specific genes and induce cell differentiation growth arrest and apoptosis through regulating histone acetylation level.
应用推荐